PALI insider trading
HealthcarePALISADE BIO, INC.: insider trade history from SEC Form 4 filings.
About PALISADE BIO, INC.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Company website: www.palisadebio.com
PALI insider activity at a glance
FilingIQ tracks 121 insider transactions for PALI in filings since Apr 29, 2021. The most recent transaction is dated Oct 19, 2026.
Across the full history, 34 open-market purchases
and 5 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest PALI Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at PALI
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for PALI?
- FilingIQ tracks 121 Form 4 insider transactions for PALI (PALISADE BIO, INC.), covering filings from Apr 29, 2021 onwards. 9 of those are dated within the last 90 days.
- Are PALI insiders net buyers or net sellers?
- Across the full Form 4 history for PALI, 34 transactions (28%) were open-market purchases and 5 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PALI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is PALI in?
- PALISADE BIO, INC. (PALI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $258.12M.
Methodology & sources
Every PALI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.